Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
42.3M
-
Number of holders
-
191
-
Total 13F shares, excl. options
-
43.6M
-
Shares change
-
+3.1M
-
Total reported value, excl. options
-
$2.24B
-
Value change
-
+$156M
-
Put/Call ratio
-
0.38
-
Number of buys
-
98
-
Number of sells
-
-105
-
Price
-
$51.37
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) as of Q1 2025
233 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) has 191 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.6M shares
.
Largest 10 shareholders include RTW INVESTMENTS, LP (3.32M shares), BlackRock, Inc. (3.15M shares), Paradigm Biocapital Advisors LP (2.61M shares), JENNISON ASSOCIATES LLC (2.49M shares), TANG CAPITAL MANAGEMENT LLC (2.45M shares), VANGUARD GROUP INC (2.23M shares), MORGAN STANLEY (2.01M shares), TORONTO DOMINION BANK (1.87M shares), Deep Track Capital, LP (1.48M shares), and Frazier Life Sciences Management, L.P. (1.4M shares).
This table shows the top 191 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.